Arimidex, Buy Arimidex, Arimidex Side Effects
images
Home       |      Services       |      Resources       |      Site Map       |      Contact Us
                MENU
icon Arimidex side effects
icon Arimidex for man
icon Arimidex anastrozole side effects
icon Arimidex tamoxifen
icon Generic arimidex
icon Arimidex atac tamoxifen
icon Arimidex medication
icon Arimidex joint pain
icon Breast cancer arimidex
icon

Arimidex and weight gain

icon Arimidex hair loss
icon Arimidex drug effects more side
icon Anastrozole arimidex man
icon Arimidex bone pain
icon Arimidex drug prescribed
   
  Featured Links
 
icon Anabolic Steroids
icon Buy Steroids
icon Buy Steroids
icon Steroid Abuse
   
   
Arimidex atac tamoxifen:
Arimidex is an aromatase inhibitor (sometimes called an AI). It is usually provided in 1MG tabs or in liquid form. The drug works in a non-steroid form by inhibiting the aromatase enzyme which convertstestosterone and other androgens into estrogen. This means that there is less estrogen tocause female pattern fat deposits, gyno, and water retention. In medicine, Arimidex isutilized to treat prostate cancer. In sports chemistry, the drug has been employed as ameans of preventing excessive estrogenic side effects during AAS use and to aid increating a harder appearing musculature for competitive bodybuilders. Unlike Nolvadex,which simply block estrogen receptor-sites, this drug prevents or reduces estrogenproduction. Though some estrogen presence is noted as necessary for AAS to reach fulleffectiveness, too much can cause a layer of fat, water retention, and breast tissue growthpotentially with tumors called gynecomastia or bitch tits. Arimidex has a 75-85%aromatization inhibition rate.

Males who experienced excessive aromatization of AAS or who were extremelyestrogen sensitive usually utilized a dosage of 0.5-3.0 mg daily. In fact, most realizedexcellent estrogen control with only 0.5mg/d (mg daily). Women usually showedexcellent lean appearances (even in their legs) with 0.5-1.0 mg daily. Arimidex has a veryshort active-life so 0.5 mg dosages were often taken 2-6 times daily at equal intervals.Stacking 10-30 mg of Nolvadex with 1.0 mg of Arimidex has resulted in a near "0"estrogen activity situation regardless of the AAS protocol utilized. Directly following anAAS cycle, estrogen control has also become a problem (during periods intended for reestablishingHPTA function). In this case, the dosage was reduced from a higher startingdosage to a low dosage that was continued for 7-14 days after AAS discontinuance. Thisprotocol was considered necessary to assure clearing of AAS induced estrogen build-up.

Reported Characteristics:
Active-Life: 4-6 hours Drug Class: Aromatase inhibitor (Oral) Average Reported Dosage: 0.5-3.0 mg daily Acne: No Water Retention: None Liver Toxic: Yes dosage dependent Decreases HPTA function: Increases it.

TRADE NAMES:
ARIMIDEX .25 MG TABS (International Pharmaceuticals) ARIMIDEX 1mg
Synutra International initiated with "outperform"
NEW YORK, March 9 (newratings.com) - Analysts at Oppenheimer & Co initiate coverage of Synutra International Inc (ticker: SYUT) with an "outperform" rating. The target price is set to $25. [more]


Linn Energy initiated with "market perform"
NEW YORK, March 9 (newratings.com) - Analysts at Wells Fargo Securities initiate coverage of Linn Energy (ticker: LINE) with a "market perform" rating. [more]


Broadwind Energy initiated with "overweight"
NEW YORK, March 9 (newratings.com) - Analysts at JP Morgan initiate coverage of Broadwind Energy Inc (ticker: BWEN) with an "overweight" rating. The target price is set to $6.5. [more]


China XD Plastics Company initiated with "buy"
NEW YORK, March 9 (newratings.com) - Analysts at Canaccord Adams initiate coverage of China XD Plastics Company Limited (ticker: CXDC) with a "buy" rating. The target price is set to $10. [more]


Patterson Companies initiated with "neutral"
NEW YORK, March 9 (newratings.com) - Analysts at UBS initiate coverage of Patterson Companies Inc (ticker: PDCO) with a "neutral" rating. The target price is set to $31. [more]


Henry Schein initiated with "neutral"
NEW YORK, March 9 (newratings.com) - Analysts at UBS initiate coverage of Henry Schein Inc (ticker: HSIC) with a "neutral" rating. The target price is set to $63. [more]


XML error: not well-formed (invalid token) at line 66